.jpg?format=webp&width=780)
A phase 3 clinical trial evaluated the efficacy and safety of two protein-based SARS-CoV-2 vaccines called FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) in Iranian adults. The study involved two cohorts: cohort 1 received a 2-dose regimen of FINLAY-FR-2, and cohort 2 received a 3-dose regimen of FINLAY-FR-2 with FINLAY-FR-1A. The trial showed that both regimens were safe and demonstrated acceptable vaccine efficacy against symptomatic COVID-19, as well as severe COVID-19 infections. The incidence of serious adverse events was very low, and there were no vaccine-related deaths. The results suggest that these vaccines could be a viable option for mass vaccination, particularly in resource-limited settings, due to their storage conditions and affordable price.
Like
Save
Share